■数字健康技术的成败取决于用户如何接受它。
■我们对使用食品和药物管理局批准的数字健康反馈系统的人员进行了用户体验(UX)评估,该系统包含可摄取传感器(IS)来捕获药物依从性。在他们规定口服暴露前预防(PrEP)以预防HIV感染后。我们对基线参与者特征进行了关联分析,看看是否出现了与积极或消极的UX相关的“角色”。
■UX数据是在一项针对HIV阴性成年人的前瞻性干预研究退出后收集的,规定的口头PrEP,并使用具有IS功能的富马酸替诺福韦酯加恩曲他滨(IS-Truvada)的数字健康反馈系统。基线人口统计学;尿液毒理学;以及评估睡眠的自我报告问卷(匹兹堡睡眠质量指数),自我效能感,习惯性的自我控制,艾滋病毒风险感知(艾滋病毒感知风险量表8项),收集抑郁症状(患者健康问卷-8)。研究中≥28天的参与者完成了Likert量表UX问卷,其中包含27个问题,分为4个领域类别:总体经验,易用性,未来使用的意图,和感知的效用。计算参与者总分数和领域子分数的均值和IQR,线性回归对与用户体验反应相关的基线参与者特征进行建模。使用Fisher精确和Wilcoxon秩和检验比较了响应者与非响应者的人口统计学特征。
■总的来说,71名参与者参加(年龄:平均37.6,范围18-69岁;n=64,90%男性;n=55,77%白人;n=24,34%西班牙裔;n=68,96%居住;n=53,75%就业)。63名使用干预措施≥28天的参与者没有观察到人口统计学差异。完成问卷的参与者更有可能被安置(52/53,98%vs8/10,80%;P=.06),尿液毒理学阳性的可能性较小(18/51,35%vs7/10,70%;P=.08)。特别是甲基苯丙胺(4/51,8%vs4/10,40%;P=0.02),而不是完成者。基于IQR值,根据总分,≥75%的参与者具有良好的UX(中位数3.78,IQR3.17-4.20),总体经验(中位数4.00,IQR3.50-4.50),易用性(中位数3.72,IQR3.33-4.22),和感知效用(中位数3.72,IQR3.22-4.25),≥50%的患者有良好的未来使用意向(中位数3.80,IQR2.80-4.40)。在多预测器建模之后,自我效能感与总分(0.822,95%CI0.405-1.240;P<.001)和所有分得分(均P<.05)显著相关。抑郁症状更多的人报告了更好的感知效用(P=0.01)。睡眠不佳与总体体验较差相关(-0.07,95%CI-0.133至-0.006;P=0.03)。
■使用启用IS的PrEP(IS-Truvada)预防HIV感染的人的UX为阳性。基线参与者特征的关联分析将较高的自我效能感与积极的UX联系起来,抑郁症状更多,感知效用更高,睡眠不足,UX为阴性。
UNASSIGNED: A digital health technology\'s success or failure depends on how it is received by users.
UNASSIGNED: We conducted a user experience (UX) evaluation among persons who used the Food and Drug Administration-approved Digital Health Feedback System incorporating ingestible sensors (ISs) to capture medication adherence, after they were prescribed oral pre-exposure prophylaxis (PrEP) to prevent HIV infection. We performed an association analysis with baseline participant characteristics, to see if \"personas\" associated with positive or negative UX emerged.
UNASSIGNED: UX data were collected upon exit from a prospective intervention study of adults who were HIV negative, prescribed oral PrEP, and used the Digital Health Feedback System with IS-enabled tenofovir disoproxil fumarate plus emtricitabine (IS-Truvada). Baseline demographics; urine toxicology; and self-report questionnaires evaluating sleep (Pittsburgh Sleep Quality Index), self-efficacy, habitual self-control, HIV risk perception (Perceived Risk of HIV Scale 8-item), and depressive symptoms (Patient Health Questionnaire-8) were collected. Participants with ≥28 days in the study completed a Likert-scale UX questionnaire of 27 questions grouped into 4 domain categories: overall experience, ease of use, intention of future use, and perceived utility. Means and IQRs were computed for participant total and domain subscores, and linear regressions modeled baseline participant characteristics associated with UX responses. Demographic characteristics of responders versus nonresponders were compared using the Fisher exact and Wilcoxon rank-sum tests.
UNASSIGNED: Overall, 71 participants were enrolled (age: mean 37.6, range 18-69 years; n=64, 90% male; n=55, 77% White; n=24, 34% Hispanic; n=68, 96% housed; and n=53, 75% employed). No demographic differences were observed in the 63 participants who used the intervention for ≥28 days. Participants who completed the questionnaire were more likely to be housed (52/53, 98% vs 8/10, 80%; P=.06) and less likely to have a positive urine toxicology (18/51, 35% vs 7/10, 70%; P=.08), particularly methamphetamine (4/51, 8% vs 4/10, 40%; P=.02), than noncompleters. Based on IQR values, ≥75% of participants had a favorable UX based on the total score (median 3.78, IQR 3.17-4.20), overall experience (median 4.00, IQR 3.50-4.50), ease of use (median 3.72, IQR 3.33-4.22), and perceived utility (median 3.72, IQR 3.22-4.25), and ≥50% had favorable intention of future use (median 3.80, IQR 2.80-4.40). Following multipredictor modeling, self-efficacy was significantly associated with the total score (0.822, 95% CI 0.405-1.240; P<.001) and all subscores (all P<.05). Persons with more depressive symptoms reported better perceived utility (P=.01). Poor sleep was associated with a worse overall experience (-0.07, 95% CI -0.133 to -0.006; P=.03).
UNASSIGNED: The UX among persons using IS-enabled PrEP (IS-Truvada) to prevent HIV infection was positive. Association analysis of baseline participant characteristics linked higher self-efficacy with positive UX, more depressive symptoms with higher perceived utility, and poor sleep with negative UX.